Global RNAi Therapeutics In-Depth Monitoring and Development Analysis Report 2023

Report ID: ARS10366 | Category: Healthcare | Pages: 99 | Format: PDF | Published Date: December 18,2023

Request Sample Enquiry before buying Ask For Discount

Single User-$3850.00 Multi User-$6200.00

Report Description
View Table of Contents

Report Summary

The global RNAi Therapeutics market size in 2022 is 808.0 million US dollars, and it is expected to be 1505.7 million US dollars by 2029, with a compound annual growth rate of 9.30% expected in 2023-2029.

MARKET COMPETITIVE LANDSCAPE:
The main players in the RNAi Therapeutics market include Quark Software Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Rexahn Pharmaceuticals, Inc. (U.S.), Silence Therapeutics (U.K.), and Arbutus Biopharma (U.S.). The share of the top 3 players in the RNAi Therapeutics market is XX%.

REGION SHARE:
The report covers the market size information of North America, Europe, Asia Pacific, Latin America, Middle East and Africa, and North America accounted for XX%, Europe accounted for XX% of RNAi Therapeutics market, and Asia Pacific accounted for XX%.

SEGMENT OVERVIEW:
The report segments the market by Type and Application. Small Interfering RNAS accounted for XX% of RNAi Therapeutics market in 2022. Microrna share of XX%.
Intradermal Injections accounted for XX% of the RNAi Therapeutics market in 2022. Pulmonary Delivery accounts for XX%.

This RNAi Therapeutics market report provides detailed information on latest developments, trade regulations, value chain optimization, market share, impact of domestic and local market players, analyzes emerging revenue sources, market regulation changes Opportunities in Aspects, Strategic Market Growth Analysis, Market Size, Category Market Growth, Application Areas and Dominance, Product Approvals, Product Launches, Geographic Expansion, Technological Innovations in the Market.

RNAi Therapeutics market country level analysis
The countries covered in the RNAi Therapeutics market report include the United States, Canada, Germany, United Kingdom, France, Russia, Japan, China, India, South Korea, Brazil, UAE, Saudi Arabia, etc.
The presence and availability of global brands and challenges due to intense or scarce competition from local and domestic brands, and trade routes are also considered while providing the predictive analysis of country data.

Competitive Landscape and RNAi Therapeutics Market Share Analysis
RNAi Therapeutics market competitive landscape provides details by competitors. The detailed information includes company profile, company financials, revenue generated, market potential, R&D investments, new market plans, global reach. The data points presented above relate only to companies relevant to the RNAi Therapeutics market.

Chapter Outline
Chapter 1: Introduces the product overview, market scope, product classification, and application division, and then includes research purposes, report timeline, and economic analysis of global regions.
Chapters 2-7: Provide Global, North America, Europe, Asia-Pacific, Latin America and Middle East & Africa RNAi Therapeutics market type, application, player and country market segmentation data.
Chapters 8-9: Segmented the global RNAi Therapeutics market by type, and application. Analyze the revenue of market segments from different perspectives.
Chapter 10: Introduces the market dynamics, the trends factors and drivers factors of the market, and the challenges and restraints faced by manufacturers in the industry, and includes industry mergers & acquisitions and industry new entrants and expansion plans.
Chapter 11: Analyzes the main companies in the RNAi Therapeutics industry, including their main businesses, products/services, revenue, gross and gross margin.
Chapter 12: The main points and conclusions of the report.

Highlights-Regions

North America
United States
Canada
Asia Pacific
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Nordic
South America
Brazil
Argentina
Colombia
Mexico
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Player list
Quark Software Inc. (U.S.)
F. Hoffmann-La Roche Ltd. (Switzerland)
Rexahn Pharmaceuticals, Inc. (U.S.)
Silence Therapeutics (U.K.)
Arbutus Biopharma (U.S.)
Benitec Biopharma (Australia)
GSK plc (U.K.)
OLIX PHARMACEUTICALS, INC. (South Korea)
Sanofi (France)
Alnylam Pharmaceuticals, Inc. (U.S.)
Moderna Inc. (U.S.)
Ionis Pharmaceuticals (U.S.)

Types list
Small Interfering RNAS
Microrna

Application list
Intradermal Injections
Pulmonary Delivery
Intravenous Injections
Intraperitoneal Injections
Others

Table of Content

1 RNAi Therapeutics Market Introduction and Overview
1.1 RNAi Therapeutics Definition
1.2 Market Size Analysis by Types
1.3 Market Size Analysis by Application
1.4 Research Purposes
1.5 Report Timeline
1.6 Economic Analysis of Global Regions
2 Global Market Growth Trends Analysis
2.1 Global RNAi Therapeutics Market Size & Forecast (2018-2029)
2.2 RNAi Therapeutics Growth Trends Analysis by Regions
2.2.1 RNAi Therapeutics Market Size by Regions: 2018 VS 2023 VS 2029
2.2.2 RNAi Therapeutics Historic Market Size by Regions (2018-2023)
2.2.3 RNAi Therapeutics Forecasted Market Size by Regions (2023-2029)
2.2.4 North America RNAi Therapeutics Market Size & Forecast (2018-2029)
2.2.5 Europe RNAi Therapeutics Market Size & Forecast (2018-2029)
2.2.6 Asia-Pacific RNAi Therapeutics Market Size & Forecast (2018-2029)
2.2.7 Latin America RNAi Therapeutics Market Size & Forecast (2018-2029)
2.2.8 Middle East & Africa RNAi Therapeutics Market Size & Forecast (2018-2029)
3 North America
3.1 North America RNAi Therapeutics Revenue by Countries
3.1.1 North America RNAi Therapeutics Revenue by Countries (2018-2029)
3.2 North America RNAi Therapeutics Revenue by Players
3.3 North America RNAi Therapeutics Revenue by Types
3.4 North America RNAi Therapeutics Revenue by Applications
3.5 United States
3.6 Canada
4 Asia Pacific
4.1 Asia Pacific RNAi Therapeutics Revenue by Countries
4.1.1 Asia Pacific RNAi Therapeutics Revenue by Countries (2018-2029)
4.2 Asia Pacific RNAi Therapeutics Revenue by Players
4.3 Asia Pacific RNAi Therapeutics Revenue by Types
4.4 Asia Pacific RNAi Therapeutics Revenue by Applications
4.5 China
4.6 Japan
4.7 Korea
4.8 Southeast Asia
4.9 India
4.10 Australia
5 Europe
5.1 Europe RNAi Therapeutics Revenue by Countries
5.1.1 Europe RNAi Therapeutics Revenue by Countries (2018-2029)
5.2 Europe RNAi Therapeutics Revenue by Players
5.3 Europe RNAi Therapeutics Revenue by Types
5.4 Europe RNAi Therapeutics Revenue by Applications
5.5 Germany
5.6 France
5.7 UK
5.8 Italy
5.9 Russia
5.10 Spain
5.11 Nordic
6 Latin America
6.1 Latin America RNAi Therapeutics Revenue by Countries
6.1.1 Latin America RNAi Therapeutics Revenue by Countries (2018-2029)
6.2 Latin America RNAi Therapeutics Revenue by Players
6.3 Latin America RNAi Therapeutics Revenue by Types
6.4 Latin America RNAi Therapeutics Revenue by Applications
6.5 Brazil
6.6 Argentina
6.7 Colombia
6.8 Mexico
7 Middle East & Africa
7.1 Middle East & Africa RNAi Therapeutics Revenue by Countries
7.1.1 Middle East & Africa RNAi Therapeutics Revenue by Countries (2018-2029)
7.2 Middle East & Africa RNAi Therapeutics Revenue by Players
7.3 Middle East & Africa RNAi Therapeutics Revenue by Types
7.4 Middle East & Africa RNAi Therapeutics Revenue by Applications
7.5 Egypt
7.6 South Africa
7.7 Israel
7.8 Turkey
7.9 GCC Countries
8 Global RNAi Therapeutics Historical and Forecast Market Analysis by Type
8.1 Global RNAi Therapeutics Revenue and Market Share by Type
8.2 Global RNAi Therapeutics Market Forecast by Type (2023-2029)
9 Global RNAi Therapeutics Historical and Forecast Market Analysis by Application
9.1 Global RNAi Therapeutics Revenue Market Share by Application (2018-2023)
9.2 RNAi Therapeutics Market Forecast by Application (2023-2029)
10 RNAi Therapeutics Industry Dynamic Analysis
10.1 RNAi Therapeutics Market Trends Analysis
10.2 RNAi Therapeutics Market Drivers Analysis
10.3 RNAi Therapeutics Market Challenges Analysis
10.4 RNAi Therapeutics Market Restraints Analysis
10.5 RNAi Therapeutics Industry Mergers & Acquisitions
10.6 RNAi Therapeutics Industry New Entrants and Expansion Plans
11 Players Profiles
11.1  Quark Software Inc. (U.S.)
11.1.1 Quark Software Inc. (U.S.) Company Profile
11.1.2 RNAi Therapeutics Product Overview
11.1.3 Quark Software Inc. (U.S.) RNAi Therapeutics Market Performance (2018-2023)
11.1.4 Quark Software Inc. (U.S.) Business Overview
11.2  F. Hoffmann-La Roche Ltd. (Switzerland)
11.2.1 F. Hoffmann-La Roche Ltd. (Switzerland) Company Profile
11.2.2 RNAi Therapeutics Product Overview
11.2.3 F. Hoffmann-La Roche Ltd. (Switzerland) RNAi Therapeutics Market Performance (2018-2023)
11.2.4 F. Hoffmann-La Roche Ltd. (Switzerland) Business Overview
11.3  Rexahn Pharmaceuticals, Inc. (U.S.)
11.3.1 Rexahn Pharmaceuticals, Inc. (U.S.) Company Profile
11.3.2 RNAi Therapeutics Product Overview
11.3.3 Rexahn Pharmaceuticals, Inc. (U.S.) RNAi Therapeutics Market Performance (2018-2023)
11.3.4 Rexahn Pharmaceuticals, Inc. (U.S.) Business Overview
11.4  Silence Therapeutics (U.K.)
11.4.1 Silence Therapeutics (U.K.) Company Profile
11.4.2 RNAi Therapeutics Product Overview
11.4.3 Silence Therapeutics (U.K.) RNAi Therapeutics Market Performance (2018-2023)
11.4.4 Silence Therapeutics (U.K.) Business Overview
11.5  Arbutus Biopharma (U.S.)
11.5.1 Arbutus Biopharma (U.S.) Company Profile
11.5.2 RNAi Therapeutics Product Overview
11.5.3 Arbutus Biopharma (U.S.) RNAi Therapeutics Market Performance (2018-2023)
11.5.4 Arbutus Biopharma (U.S.) Business Overview
11.6  Benitec Biopharma (Australia)
11.6.1 Benitec Biopharma (Australia) Company Profile
11.6.2 RNAi Therapeutics Product Overview
11.6.3 Benitec Biopharma (Australia) RNAi Therapeutics Market Performance (2018-2023)
11.6.4 Benitec Biopharma (Australia) Business Overview
11.7  GSK plc (U.K.)
11.7.1 GSK plc (U.K.) Company Profile
11.7.2 RNAi Therapeutics Product Overview
11.7.3 GSK plc (U.K.) RNAi Therapeutics Market Performance (2018-2023)
11.7.4 GSK plc (U.K.) Business Overview
11.8  OLIX PHARMACEUTICALS, INC. (South Korea)
11.8.1 OLIX PHARMACEUTICALS, INC. (South Korea) Company Profile
11.8.2 RNAi Therapeutics Product Overview
11.8.3 OLIX PHARMACEUTICALS, INC. (South Korea) RNAi Therapeutics Market Performance (2018-2023)
11.8.4 OLIX PHARMACEUTICALS, INC. (South Korea) Business Overview
11.9  Sanofi (France)
11.9.1 Sanofi (France) Company Profile
11.9.2 RNAi Therapeutics Product Overview
11.9.3 Sanofi (France) RNAi Therapeutics Market Performance (2018-2023)
11.9.4 Sanofi (France) Business Overview
11.10  Alnylam Pharmaceuticals, Inc. (U.S.)
11.10.1 Alnylam Pharmaceuticals, Inc. (U.S.) Company Profile
11.10.2 RNAi Therapeutics Product Overview
11.10.3 Alnylam Pharmaceuticals, Inc. (U.S.) RNAi Therapeutics Market Performance (2018-2023)
11.10.4 Alnylam Pharmaceuticals, Inc. (U.S.) Business Overview
11.11  Moderna Inc. (U.S.)
11.11.1 Moderna Inc. (U.S.) Company Profile
11.11.2 RNAi Therapeutics Product Overview
11.11.3 Moderna Inc. (U.S.) RNAi Therapeutics Market Performance (2018-2023)
11.11.4 Moderna Inc. (U.S.) Business Overview
11.12  Ionis Pharmaceuticals (U.S.)
11.12.1 Ionis Pharmaceuticals (U.S.) Company Profile
11.12.2 RNAi Therapeutics Product Overview
11.12.3 Ionis Pharmaceuticals (U.S.) RNAi Therapeutics Market Performance (2018-2023)
11.12.4 Ionis Pharmaceuticals (U.S.) Business Overview
12 Research Findings and Conclusion

FAQ's

What does the report cover (Scope)?

It contains all the geographic trends, and market analysis for global market

ENTER REPORT NAME TO SEARCH

Global RNAi Therapeutics In-Depth Monitoring and Development Analysis Report 2023

Report Summary

Table of Contents

FAQ's

What does the report cover (Scope)?